2C-I-NBOMe, an “N-bomb” that kills with “Smiles”. Toxicological and legislative aspects

References

• Advisory Council on the Misuse of Drugs (ACMD). (2013). “NBOMe” compounds: a review of the evidence of use and harm. Available at: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/204808/J_TCDO_report_on_5-6APB_and_NBOMe_compounds.pdf. Accessed on October 31, 2013
   Google Scholar
• Baselt RC. (2004). Disposition of toxic drugs and chemicals in man. 7th ed. Foster City (CA): Biomedical Publications
   Google Scholar
• Blaazer AR, Smid P, Kruse CG. (2008). Structure-activity relationships of phenylalkylamines as agonist ligands for 5-HT(2A) receptors. Chem Med Chem 3:1299–1309
   Web of Science ®Google Scholar
• Braden MR, Parrish JC, Naylor JC, Nichols DE. (2006). Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists. Mol Pharmacol 70:1956–1964
   PubMed Web of Science ®Google Scholar
• Casale JF, Hays PA. (2012). Characterization of Eleven 2,5-Dimethoxy-N-(2-methoxybenzyl)phenethylamine (NBOMe) Derivatives and Differentiation from their 3- and 4-Methoxybenzyl Analogues – Part I. Microgram J 9:84–109
   Google Scholar
• Dean BV, Stellpflug SJ, Burnett AM, Engebretsen KM. (2013). 2C or not 2C: phenethylamine designer drug review. J Med Toxicol 9:172–178
   PubMedGoogle Scholar
• Dipartimento Politiche Antidroga, Presidenza Del Consiglio Del Ministri. (2013). New Drugs, Nuove Sostanze Psicoattive. 25I-NBOMe, Fenetilammine. Available at: http://www.politicheantidroga.it/media/605143/4_fenetilammine_a.pdf. Accessed on October 30, 2013
   Google Scholar
• Drug Enforcement Administration (DEA), DEA, NBOMe. (2013). 25I-NBOMe, 25C-NBOMe, and 25B-NBOMe (Street names: N-bomb, Smiles, 25I, 25C, 25B). Office of Diversion Control, Drug & Chemical Evaluation Section
   Google Scholar
• Drug Enforcement Administration, DEA Final order. Department of Justice. (2013). Schedules of controlled substances: temporary placement of three synthetic phenethylamines into Schedule I. Federal Register 78:68716–68719
   PubMedGoogle Scholar
• Ettrup A, Hansen M, Santini MA, et al. (2011). Radiosynthesis and in vivo evaluation of a series of substituted 11C-phenethylamines as 5-HT2A agonist PET tracers. Eur J Nucl Med Mol Imaging 38:681–693
   PubMed Web of Science ®Google Scholar
• European Database on New Drugs (EDND). (2014). European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), Phenethylamines, 25I-NBOMe. Available at: https://ednd.emcdda.europa.eu/html.cfm/index7246EN.html. Accessed on March 6, 2014
   Google Scholar
• European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). New drugs in Europe, 2012. EMCDDA-Europol 2012 Annual Report on the implementation of Council Decision 2005/387/JHA. Available at: http://www.emcdda.europa.eu/publications/implementation-reports/2012. Accessed on October 30, 2013
   Google Scholar
• Forendex forum. Southern Association of Forensic Scientists. (2013). Available at: http://forendex.southernforensic.org/index.php/detail/index/1145. Accessed on November 4, 2013
   Google Scholar
• Freye E. (2009). Peyote, a mescaline-containing cactus. In: Freye E, Levy JV, eds. Pharmacology and abuse of cocaine, amphetamines, ecstasy and related designer drugs. Germany: Springer Science and Business Media B.V., 227–228
   Google Scholar
• Halberstadt AL, Geyer MA. (2013). Characterization of the head-twitch response induced by hallucinogens in mice: detection of the behavior based on the dynamics of head movement. Psychopharmacology 227:727–739
   PubMed Web of Science ®Google Scholar
• Halberstadt AL, Geyer MA. (2014). Effects of the hallucinogen 2,5-dimethoxy-4-iodophenethylamine (2C-I) and superpotent N-benzyl derivatives on the head twitch response. Neuropharmacology 77:200–207
   PubMed Web of Science ®Google Scholar
• Heim R. (2003). Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2-Methoxybenzyl-Partialstruktur. Entwicklung eines neuen Struktur-Wirkungskonzepts. (in German). Available at: http://www.diss.fu-berlin.de/diss/receive/FUDISS_thesis_000000001221. Accessed on October 30, 2013
   Google Scholar
• Hill SL, Doris T, Gurung S, et al. (2013). Severe clinical toxicity associated with analytically confirmed recreational use of 25I-NBOMe: case series. Clin Toxicol 51:487–492
   PubMed Web of Science ®Google Scholar
• Hill SL, Thomas SH. (2011). Clinical toxicology of newer recreational drugs. Clin Toxicol 49:705–719
   PubMed Web of Science ®Google Scholar
• Home Office, GOV.UK. News story, “NBOMe” and “Benzofury” banned. (2013). Available at: https://www.gov.uk/government/news/nbome-and-benzofury-to-be-banned. Accessed on October 30, 2013
   Google Scholar
• Israel, Legal Status. (2013). Available at: http://www.health.gov.il/LegislationLibrary/25574413.pdf. Accessed on January 10, 2014
   Google Scholar
• Jerry J, Collins G, Streem D. (2012). Synthetic legal intoxicating drugs: the emerging ‘incense’ and ‘bath salt’ phenomenon. Cleve Clin J Med 79:258–264
   PubMed Web of Science ®Google Scholar
• Kelly A, Eisenga B, Riley B, Judge B. (2012). Case series of 25I-NBOMe exposures with laboratory confirmation. Abstract in 2012 Annual Meeting of the NACCT. Clin Toxicol 50:702
   Google Scholar
• L 321/64. (2003). Council Decision 2003/847/JHA of 27 November 2003 concerning control measures and criminal sanctions in respect of the new synthetic drugs 2C-I, 2C-T-2, 2C-T-7 and TMA-2. Available at: http://db.eurocrim.org/db/en/doc/833.pdf. Accessed on November 4, 2013
   Google Scholar
• Läkemedelsverkets författningssamling. Föreskrifter om ändring i Läkemedelsverkets föreskrifter (LVFS 2011:10) om förteckningar över narkotika. (2013). (In Swedish). Available at: http://www.lakemedelsverket.se/upload/lvfs/LVFS_2013-15.pdf. Accessed on October 30, 2013
   Google Scholar
• Leth-Petersen S, Bundgaard C, Hansen M, Carnerup MA, Kehler J, Kristensen JL. (2014). Correlating the metabolic stability of psychedelic 5-HT2A agonists with anecdotal reports of human oral bioavailability. Neurochem Res. [Epub ahead of print]. doi: 10.1007/s11064-014-1253-y
   Google Scholar
• Loeffler G, Hurst D, Penn A, Yung K. (2012). Spice, bath salts, and the U.S. military: the emergence of synthetic cannabinoid receptor agonists and cathinones in the U.S. Armed Forces. Mil Med 177:1041–1048
   PubMed Web of Science ®Google Scholar
• Nichols DE, Frescas SP, Chemel BR, et al. (2008). High specific activity tritium-labeled N-(2-methoxybenzyl)-2,5-dimethoxy-4-iodophenethylamine (INBMeO): a high-affinity 5-HT2A receptor-selective agonist radioligand. Bioorg Med Chem 16:6116–6123
   PubMed Web of Science ®Google Scholar
• Nichols DE. (2004). Hallucinogens. Pharmacol Ther 101:131–181
   PubMed Web of Science ®Google Scholar
• Poklis JL, Charles J, Wolf CE, Poklis A. (2013). High-performance liquid chromatography tandem mass spectrometry method for the determination of 2CC-NBOM and 25I-NBOMe in human serum. Biomed Chromatogr 27:1794–1800
   Google Scholar
• Poklis JL, Clay DJ, Poklis A. (2014b). High-performance liquid chromatography with tandem mass spectrometry for the determination of nine hallucinogenic 25-NBOMe designer drugs in urine specimens. J Anal Toxicol 38:113–121
   Google Scholar
• Poklis JL, Devers KG, Arbefeville EF, et al. (2014a). Postmortem detection of 25I-NBOMe [2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine] in fluids and tissues determined by high performance liquid chromatography with tandem mass spectrometry from a traumatic death. Forensic Sci Int 234:14–20
   PubMed Web of Science ®Google Scholar
• Rose RS, Cumpston KL, Stromberg PE, Wills BK. (2012). Severe poisoning following self-reported use of 25-I, a novel substituted amphetamine. Abstract in 2012 Annual Meeting of the NACCT. Clin Toxicol 50:707–8
   Google Scholar
• Rose SR, Poklis JL, Poklis A. (2013). A case of 25I-NBOMe (25-I) intoxication: a new potent 5-HT2A agonist designer drug. Clin Toxicol 51:174–177
   PubMed Web of Science ®Google Scholar
• Scientific Working Group for the Analysis of Seized Drugs (SWGDRUG). 25I-NBOMe. Available at: http://www.swgdrug.org/Monographs/25I-NBOMe.pdf. Accessed on November 5, 2013
   Google Scholar
• Shulgin A, Shulgin A. (1991). Phenethylamines I Have Known and Love, PiHKAL: a chemical love story. Berkeley (CA): Transform Press
   Google Scholar
• Stellpflug SJ, Kealey SE, Hegarty CB, Janis GC. (2014). 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe): clinical case with unique confirmatory testing. J Med Toxicol 10:45–50
   Google Scholar
• United Nations Office on Drugs and Crime (UNODC). (2013). Global Smart Update 2013. Available at: http://www.unodc.org/documents/scientific/Global_SMART_Update_9_web.pdf. Accessed on October 30, 2013
   Google Scholar
• Walterscheid JP, Phillips GT, Lopez AE, et al. (2014). Pathological findings in 2 cases of fatal 25I-NBOMe toxicity. Am J Forensic Med Pathol 35:20–25
   PubMed Web of Science ®Google Scholar
• Zuba D, Sekula K, Buczek A. (2013). 25C-NBOMe – new potent hallucinogenic substance identified on the drug market. Forensic Sci Int 227:7–14
   PubMed Web of Science ®Google Scholar